1. Home
  2. CNMD vs WVE Comparison

CNMD vs WVE Comparison

Compare CNMD & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNMD
  • WVE
  • Stock Information
  • Founded
  • CNMD 1970
  • WVE 2012
  • Country
  • CNMD United States
  • WVE Singapore
  • Employees
  • CNMD N/A
  • WVE N/A
  • Industry
  • CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNMD Health Care
  • WVE Health Care
  • Exchange
  • CNMD Nasdaq
  • WVE Nasdaq
  • Market Cap
  • CNMD 1.7B
  • WVE 1.7B
  • IPO Year
  • CNMD 1987
  • WVE 2015
  • Fundamental
  • Price
  • CNMD $48.59
  • WVE $5.92
  • Analyst Decision
  • CNMD Buy
  • WVE Strong Buy
  • Analyst Count
  • CNMD 5
  • WVE 11
  • Target Price
  • CNMD $77.20
  • WVE $22.00
  • AVG Volume (30 Days)
  • CNMD 536.8K
  • WVE 1.7M
  • Earning Date
  • CNMD 04-30-2025
  • WVE 05-08-2025
  • Dividend Yield
  • CNMD 1.65%
  • WVE N/A
  • EPS Growth
  • CNMD 108.33
  • WVE N/A
  • EPS
  • CNMD 4.25
  • WVE N/A
  • Revenue
  • CNMD $1,307,015,000.00
  • WVE $108,302,000.00
  • Revenue This Year
  • CNMD $5.97
  • WVE N/A
  • Revenue Next Year
  • CNMD $5.63
  • WVE N/A
  • P/E Ratio
  • CNMD $11.43
  • WVE N/A
  • Revenue Growth
  • CNMD 5.00
  • WVE N/A
  • 52 Week Low
  • CNMD $47.25
  • WVE $4.25
  • 52 Week High
  • CNMD $78.58
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • CNMD 32.11
  • WVE 33.76
  • Support Level
  • CNMD $47.25
  • WVE $5.28
  • Resistance Level
  • CNMD $57.17
  • WVE $6.41
  • Average True Range (ATR)
  • CNMD 3.25
  • WVE 0.62
  • MACD
  • CNMD -0.81
  • WVE -0.00
  • Stochastic Oscillator
  • CNMD 9.65
  • WVE 20.51

About CNMD CONMED Corporation

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: